Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    NovaBay Pharmaceuticals I...

    AMEX: NBY · Real-Time Price · USD
    0.59
    0.00 (0.05%)
    At close: Jun 06, 2025, 3:59 PM
    0.57
    -2.78%
    After-hours: Jun 06, 2025, 05:18 PM EDT

    NovaBay Pharmaceuticals Statistics

    Share Statistics

    NovaBay Pharmaceuticals has 5.82M shares outstanding. The number of shares has increased by 438.09% in one year.

    Shares Outstanding

    n/a
    		 5.82M

    Shares Change (YoY)

    n/a
    		 438.09%

    Shares Change (QoQ)

    n/a
    		 19.05%

    Owned by Institutions (%)

    n/a
    		 0%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 43

    FTD / Avg. Volume

    n/a
    		 0.09%

    Short Selling Information

    The latest short interest is 42.79K, so 0.74% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 42.79K

    Short % of Shares Out

    n/a
    		 0.74%

    Short % of Float

    n/a
    		 0.82%

    Short Ratio (days to cover)

    n/a
    		 1

    Valuation Ratios

    The PE ratio is -0.28 and the forward PE ratio is -1.57. NovaBay Pharmaceuticals's PEG ratio is 0.

    PE Ratio

    n/a
    		 -0.28

    Forward PE

    n/a
    		 -1.57

    PS Ratio

    n/a
    		 0.21

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 -15.82

    P/FCF Ratio

    n/a
    		 -0.39

    PEG Ratio

    n/a
    		 0
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for NovaBay Pharmaceuticals.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 0.68, with a Debt / Equity ratio of -12.96.

    Current Ratio

    n/a
    		 0.68

    Quick Ratio

    n/a
    		 0.41

    Debt / Equity

    n/a
    		 -12.96

    Debt / EBITDA

    n/a
    		 -0.28

    Debt / FCF

    n/a
    		 -0.32

    Interest Coverage

    n/a
    		 -6.46

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $752,384.62

    Profits Per Employee

    n/a
    		 $-555,615.38

    Employee Count

    n/a
    		 13

    Asset Turnover

    n/a
    		 2.86

    Inventory Turnover

    n/a
    		 4.31

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -80.2% in the last 52 weeks. The beta is 0.41, so NovaBay Pharmaceuticals's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.41

    52-Week Price Change

    n/a
    		 -80.2%

    50-Day Moving Average

    n/a
    		 0.57

    200-Day Moving Average

    n/a
    		 0.61

    Relative Strength Index (RSI)

    n/a
    		 56.02

    Average Volume (20 Days)

    n/a
    		 49,753

    Income Statement

    In the last 12 months, NovaBay Pharmaceuticals had revenue of 9.78M and earned -7.22M in profits. Earnings per share was -2.53.

    Revenue

    n/a
    		 9.78M

    Gross Profit

    n/a
    		 6.48M

    Operating Income

    n/a
    		 -5.84M

    Net Income

    n/a
    		 -7.22M

    EBITDA

    n/a
    		 -5.92M

    EBIT

    n/a
    		 -6.31M

    Earnings Per Share (EPS)

    n/a
    		 -2.53
    Full Income Statement

    Balance Sheet

    The company has 430K in cash and 1.67M in debt, giving a net cash position of -1.24M.

    Cash & Cash Equivalents

    n/a
    		 430K

    Total Debt

    n/a
    		 1.67M

    Net Cash

    n/a
    		 -1.24M

    Retained Earnings

    n/a
    		 -183.46M

    Total Assets

    n/a
    		 9.87M

    Working Capital

    n/a
    		 5.97M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -5.18M and capital expenditures -6K, giving a free cash flow of -5.19M.

    Operating Cash Flow

    n/a
    		 -5.18M

    Capital Expenditures

    n/a
    		 -6K

    Free Cash Flow

    n/a
    		 -5.19M

    FCF Per Share

    n/a
    		 -1.53
    Full Cash Flow Statement

    Margins

    Gross margin is 66.26%, with operating and profit margins of -59.7% and -73.85%.

    Gross Margin

    n/a
    		 66.26%

    Operating Margin

    n/a
    		 -59.7%

    Pretax Margin

    n/a
    		 -73.71%

    Profit Margin

    n/a
    		 -73.85%

    EBITDA Margin

    n/a
    		 -60.58%

    EBIT Margin

    n/a
    		 -59.7%

    FCF Margin

    n/a
    		 -53.05%

    Dividends & Yields

    NBY does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for NBY is $0.85, which is 44.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $0.85

    Price Target Difference

    n/a
    		 44.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 31, 2024. It was a backward split with a ratio of 1:35.

    Last Split Date

    n/a
    		 May 31, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:35

    Scores

    Altman Z-Score

    n/a
    		 -25.21

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist